Rabbit Recombinant Monoclonal Cytochrome P450 17A1/CYP17A1 antibody - conjugated to HRP. Suitable for WB and reacts with Human samples.
pH: 7.4
Preservative: 0.1% Proclin 300 Solution
Constituents: PBS, 30% Glycerol (glycerin, glycerine), 1% BSA
WB | |
---|---|
Human | Tested |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 1/5000 | Notes - |
Select an associated product type
A cytochrome P450 monooxygenase involved in corticoid and androgen biosynthesis (PubMed:22266943, PubMed:25301938, PubMed:27339894, PubMed:9452426). Catalyzes 17-alpha hydroxylation of C21 steroids, which is common for both pathways. A second oxidative step, required only for androgen synthesis, involves an acyl-carbon cleavage. The 17-alpha hydroxy intermediates, as part of adrenal glucocorticoids biosynthesis pathway, are precursors of cortisol (Probable) (PubMed:25301938, PubMed:9452426). Hydroxylates steroid hormones, pregnenolone and progesterone to form 17-alpha hydroxy metabolites, followed by the cleavage of the C17-C20 bond to form C19 steroids, dehydroepiandrosterone (DHEA) and androstenedione (PubMed:22266943, PubMed:25301938, PubMed:27339894, PubMed:36640554, PubMed:9452426). Has 16-alpha hydroxylase activity. Catalyzes 16-alpha hydroxylation of 17-alpha hydroxy pregnenolone, followed by the cleavage of the C17-C20 bond to form 16-alpha-hydroxy DHEA (PubMed:36640554). Also 16-alpha hydroxylates androgens, relevant for estriol synthesis (PubMed:25301938, PubMed:27339894). Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (CPR; NADPH-ferrihemoprotein reductase) (PubMed:22266943, PubMed:25301938, PubMed:27339894, PubMed:9452426).
CYP17, S17AH, CYP17A1, 17-alpha-hydroxyprogesterone aldolase, CYPXVII, Cytochrome P450 17A1, Cytochrome P450-C17, Steroid 17-alpha-monooxygenase, Cytochrome P450c17
Rabbit Recombinant Monoclonal Cytochrome P450 17A1/CYP17A1 antibody - conjugated to HRP. Suitable for WB and reacts with Human samples.
pH: 7.4
Preservative: 0.1% Proclin 300 Solution
Constituents: PBS, 30% Glycerol (glycerin, glycerine), 1% BSA
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
This product is a recombinant monoclonal antibody, which offers several advantages including:
For more information, read more on recombinant antibodies.
Cytochrome P450 17A1 also known as CYP17A1 is an essential enzyme in the steroidogenic pathway. Its molecular mass is approximately 57 kDa. It is part of the cytochrome P450 family and shows expression primarily in the adrenal glands and gonads. This enzyme catalyzes two key reactions: the 17α-hydroxylation of pregnenolone and progesterone and the subsequent 1720-lyase reaction. These reactions are critical for the production of steroid hormones such as glucocorticoids and sex steroids.
CYP17A1 plays a central role in hormone biosynthesis. The enzyme exists as a single protein and does not form part of a larger complex. By facilitating the conversion of progestogens into androgens it directly impacts the balance and levels of steroid hormones in the body. This function supports vital processes like the development of secondary sexual characteristics and the regulation of metabolism therefore affecting multiple physiological functions.
CYP17A1 integrates into both the steroidogenesis and biosynthesis pathways of adrenal and sex hormones. It links directly with proteins such as steroidogenic acute regulatory protein (StAR) and cytochrome P450 oxidoreductase (POR) which assist in enabling its enzymatic function. These pathways regulate the levels of hormones influencing biological processes including stress responses and reproductive functions.
CYP17A1 is associated with conditions like congenital adrenal hyperplasia and prostate cancer. In congenital adrenal hyperplasia CYP17A1 mutations disrupt the steroidogenesis pathway leading to cortisol production deficiency. In prostate cancer CYP17A1 is often upregulated contributing to increased androgen levels that fuel cancer progression. Proteins such as 3β-hydroxysteroid dehydrogenase (3β-HSD) and androgen receptor (AR) interact with CYP17A1 in these disorders demonstrating its importance in disease mechanisms.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
This blot was produced using a 4-12% Bis-tris gel under the MOPS buffer system. The gel was run at 200V for 50 minutes before being transferred onto a Nitrocellulose membrane at 30V for 70 minutes. The membrane was then blocked for an hour using 3% milk before being incubated with ab204022 overnight at 4°C. Antibody binding was visualised using ECL development solution ECL Substrate Kit (High Sensitivity) ab133406.
All lanes: Western blot - HRP Anti-Cytochrome P450 17A1/CYP17A1 antibody [EPR6293] (ab204022) at 1/5000 dilution
Lane 1: Western blot - HeLa whole cell lysate (HeLa whole cell lysate ab150035) at 10 µg
Lane 2: Jurkat (Human T cell lymphoblast-like cell line) Whole Cell Lysate at 10 µg
Developed using the ECL technique.
Performed under reducing conditions.
Predicted band size: 57 kDa
Observed band size: 57 kDa
Exposure time: 3min
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com